Compare PRPL & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | TPST |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 13.7M |
| IPO Year | 2015 | 2012 |
| Metric | PRPL | TPST |
|---|---|---|
| Price | $2.27 | $0.64 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.63 | N/A |
| AVG Volume (30 Days) | 44.1K | ★ 2.1M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $468,725,000.00 | $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $0.64 |
| 52 Week High | $10.00 | $11.13 |
| Indicator | PRPL | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 40.77 | 34.71 |
| Support Level | $0.36 | N/A |
| Resistance Level | $10.00 | $1.24 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 58.49 | 8.57 |
Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.